(FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q3)Mar 31, 2020 | (FY)Dec 31, 2019 | (Q3)Mar 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | ---- | ---- | --15.93M | --2.96M | ---- | ---- | -20.77%10.33M | ---- | 89.47%13.04M | --1.32M |
Operating income | 15.93M | 2.96M | -20.77%10.33M | 89.47%13.04M | 1.32M | |||||
Cost of sales | ---- | ---- | ---983K | ---787K | ---- | ---- | 72.85%-2.6M | ---- | -75.39%-9.56M | ---919K |
Operating expenses | -983K | -787K | 72.85%-2.6M | -75.39%-9.56M | -919K | |||||
Gross profit | 14.95M | 2.17M | 122.46%7.74M | 143.15%3.48M | 396K | |||||
Selling expenses | ---- | ---- | 15.68%-83.14M | -132.52%-63.05M | ---98.6M | ---27.12M | ---- | ---- | ---- | ---- |
Administrative expenses | 6.63%-125.24M | 13.59%-72.64M | 35.31%-134.13M | 28.41%-84.06M | 14.12%-207.35M | ---117.42M | -170.17%-241.44M | -476.79%-32.79M | -301.02%-89.37M | ---5.68M |
Research and development expenses | 3.36%-564.28M | 23.84%-224.78M | 4.71%-583.88M | -8.70%-295.14M | 12.04%-612.72M | ---271.53M | -58.74%-696.57M | -58.41%-111.44M | -61.63%-438.82M | ---70.35M |
Impairment and provision | ---8.92M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairment is provision | ---8.92M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of operating profit | -466.01%-12.76M | -64.33%1.64M | -94.15%3.49M | -79.03%4.58M | 103.02%59.56M | --21.86M | -47,808.42%-1.97B | -8.45%1.44M | -57.58%4.14M | --1.57M |
Operating profit | 9.14%-711.2M | 32.08%-295.78M | 8.89%-782.72M | -10.47%-435.5M | 70.41%-859.11M | -394.21M | -457.66%-2.9B | -92.78%-142.79M | -84.20%-520.57M | -74.07M |
Financing income | -34.84%34.74M | -27.48%20.29M | 124.68%53.31M | 275.64%27.97M | 538.73%23.73M | --7.45M | 495.35%3.72M | -37.77%201K | -61.00%624K | --323K |
Financing cost | 65.54%-1.04M | 61.67%-662K | 90.25%-3.02M | 91.25%-1.73M | 77.43%-30.93M | ---19.73M | -3,613.82%-137M | -69.28%-970K | 47.83%-3.69M | ---573K |
Earning before tax | 7.50%-677.5M | 32.52%-276.16M | 15.45%-732.42M | -0.68%-409.25M | 71.47%-866.31M | -406.49M | -479.85%-3.04B | -93.17%-143.56M | -81.77%-523.64M | -74.32M |
Tax | 12.65%2.28M | -57.59%1.12M | 117.17%2.02M | -33.32%2.63M | -83.95%932K | --3.95M | 551.63%5.81M | --1.04M | --891K | ---- |
After-tax profit from continuing operations | 7.55%-675.22M | 32.36%-275.04M | 15.60%-730.4M | -1.01%-406.62M | 71.44%-865.37M | -402.54M | -479.73%-3.03B | -91.77%-142.52M | -81.46%-522.75M | -74.32M |
Earning after tax | 7.55%-675.22M | 32.36%-275.04M | 15.60%-730.4M | -1.01%-406.62M | 71.44%-865.37M | -402.54M | -479.73%-3.03B | -91.77%-142.52M | -81.46%-522.75M | -74.32M |
Minority profit | -369.23%-854K | 50.25%-491K | -21.33%-182K | 40.22%-987K | 95.59%-150K | ---1.65M | -412.35%-3.4M | ---552K | ---664K | ---- |
Profit attributable to shareholders | 7.65%-674.36M | 32.31%-274.55M | 15.60%-730.21M | -1.18%-405.63M | 71.42%-865.22M | -400.89M | -479.81%-3.03B | -91.03%-141.97M | -81.23%-522.08M | -74.32M |
Basic earnings per share | 8.28%-1.33 | 33.33%-0.54 | 17.14%-1.45 | 1.22%-0.81 | 85.84%-1.75 | -0.82 | -553.97%-12.36 | -88.89%-0.51 | -68.75%-1.89 | -0.27 |
Diluted earnings per share | 8.28%-1.33 | 34.15%-0.54 | 18.08%-1.45 | 0.00%-0.82 | 85.68%-1.77 | -0.82 | -553.97%-12.36 | -88.89%-0.51 | -68.75%-1.89 | -0.27 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data